Ixoreal Biomed highlights an exploratory placebo-controlled study of SRI-81 Shatavari, alone and combined with KSM-66 Ashwagandha, published in the International Journal of Women’s Health.
Feature|Sponsored|June 18, 2026
Pycnogenol® and the Science of Women's Wellness with Horphag Research
Author(s)Joel Melillo, Horphag Research
Key Takeaways
- Understand the clinical evidence base behind Pycnogenol®, including its antioxidant, anti-inflammatory, and circulatory benefits.
- Learn how Horphag Research bridges the gap between clinical science and consumer-facing brand communication.
Joel Melillo of Horphag Research discusses the clinical evidence behind Pycnogenol® and the company's expanding focus on women's health, from menopause to skin and circulatory benefits.
Advertisement
Joel Melillo, Vice President of Sales & Marketing at Horphag Research, unpacks the science behind Pycnogenol®, a natural antioxidant and anti-inflammatory backed by more than 160 clinical studies and 13,000 patients. Melillo discusses how Horphag is deepening its research into women's health, including menopause, hormone balance, and circulatory support. Learn how the company translates that clinical depth into communication that establishes trust with consumers.
Advertisement
Related to this article
Clinical research moves beyond compliance, focusing on smarter trial design, risk-based quality, and “evidence engineering” to deliver decisive, decision-ready results.
The company says the innovation, built on its CoreNhanced BioJourney platform, is designed for beverage and gummy formats.
AuraFen, BILVORA, and IMBE debut at SupplySide Global 2026, and the company will also highlight its CaFi digestive health ingredient.
Horphag Research's Sébastien Bornet breaks down the clinical science behind Robuvit, exploring how the caffeine-free French oak extract supports mitochondrial energy, mood stability, and stress resilience.
Todd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules while advocating for federal uniformity.
FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.
The company plans to present Organicaps capsules in size 0, 25 years of UC-II, and liquid-filled capsule technology.
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and Canada
2
FDA Finalizes NDI Guidance on Identity and Safety Information, Leaving Some Industry Concerns Open
3
Thirty Years of GCP: The Evolution From Study Execution to Evidence Generation
4
CoreFX Launches CreaSHLD-IN Shielded Creatine at SupplySide Global 2026
5